Dabigatran and Warfarin for secondary prevention of stroke in Atrial fibrillation patients: A nationwide cohort study

American Journal of Medicine

Volumn 127, Issue 12, 2014, Pages 1172-1178.e5

  Larsen, Torben Bjerregaard ^a,b   Rasmussen, Lars Hvilsted ^b   Gorst Rasmussen, Anders ^a,b   Skjøth, Flemming ^a,b   Lane, Deirdre A ^c   Lip, Gregory Y H ^b,c  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b AALBORG UNIVERSITY   (Denmark)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Antithrombotic therapy; Atrial fibrillation; Comparative effectiveness; Dabigatran; Stroke; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DABIGATRAN; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE REGISTRY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OBSERVATIONAL STUDY; RISK ASSESSMENT; SECONDARY PREVENTION; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; COMPARATIVE STUDY; COMPLICATION; DENMARK; ISCHEMIC ATTACK, TRANSIENT; MIDDLE AGED; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REGISTER; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; COHORT STUDIES; DENMARK; FEMALE; HUMANS; ISCHEMIC ATTACK, TRANSIENT; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REGISTRIES; SECONDARY PREVENTION; STROKE; TREATMENT OUTCOME; WARFARIN;

EID: 84919667464     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2014.07.023     Document Type: Article

References (22)

1. I.E. Albertsen, L.H. Rasmussen, T.F. Overvad, T. Graungaard, T.B. Larsen, and G.Y.H. Lip Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis Stroke 44 5 2013 1329 1336
2. A. Banerjee, F. Marín, and G.Y.H. Lip A new landscape for stroke prevention in atrial fibrillation: focus on new anticoagulants, antiarrhythmic drugs, and devices Stroke 42 11 2011 3316 3322
3. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 12 2009 1139 1151
4. T.B. Larsen, L.H. Rasmussen, and F. Skjøth Efficacy and safety of dabigatran etexilate and warfarin in "real-world" patients with atrial fibrillation: a prospective nationwide cohort study J Am Coll Cardiol 61 22 2013 2264 2273
5. R. Sørensen, G. Gislason, and C. Torp-Pedersen Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study BMJ Open 3 5 2013 e002758
6. H.-C. Diener, S.J. Connolly, and M.D. Ezekowitz Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial Lancet Neurol 9 12 2010 1157 1163
7. L.H. Rasmussen, T.B. Larsen, T. Graungaard, F. Skjøth, and G.Y.H. Lip Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis BMJ 345 2012 e7097
8. T.B. Larsen, L.H. Rasmussen, and A. Gorst-Rasmussen Myocardial ischemic events in "real world" patients with atrial fibrillation treated with dabigatran or warfarin Am J Med 127 4 2014 329 336.e4
9. T.B. Larsen, A. Gorst-Rasmussen, L.H. Rasmussen, F. Skjøth, M. Rosenzweig, and G.Y.H. Lip Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation Am J Med 127 7 2014 650 656
10. D.A. Lane, and G.Y.H. Lip Dabigatran in atrial fibrillation: balancing secondary stroke prevention against bleeding risk Lancet Neurol 9 12 2010 1140 1142
11. M.D. Ezekowitz, L. Wallentin, and S.J. Connolly Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation Circulation 122 22 2010 2246 2253
12. H.W. Kildemoes, H.T. Sørensen, and J. Hallas The Danish National Prescription Registry Scand J Public Health 39 7 Suppl 2011 38 41
13. E. Lynge, J.L. Sandegaard, and M. Rebolj The Danish National Patient Register Scand J Public Health 39 7 Suppl 2011 30 33
14. C.B. Pedersen The Danish Civil Registration System Scand J Public Health 39 7 Suppl 2011 22 25
15. T.A. Gooley, W. Leisenring, J. Crowley, and B.E. Storer Estimation of failure probabilities in the presence of competing risks: new representations of old estimators Stat Med 18 6 1999 695 706
16. F. Dentali, N. Riva, M. Crowther, A.G.G. Turpie, G.Y.H. Lip, and W. Ageno Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature Circulation 126 20 2012 2381 2391
17. M.R. Patel, K.W. Mahaffey, and J. Garg Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 10 2011 883 891
18. K.W. Mahaffey, A.S. Hellkamp, and M.R. Patel End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience Circ Cardiovasc Qual Outcomes 6 4 2013 470 478
19. S. Schneeweiss, J.J. Gagne, A.R. Patrick, N.K. Choudhry, and J. Avorn Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation Circ Cardiovasc Qual Outcomes 5 4 2012 480 486
20. D.Y. Lin, B.M. Psaty, and R.A. Kronmal Assessing the sensitivity of regression results to unmeasured confounders in observational studies Biometrics 54 3 1998 948 963
21. L.-H. Krarup, G. Boysen, H. Janjua, E. Prescott, and T. Truelsen Validity of stroke diagnoses in a National Register of Patients Neuroepidemiology 28 3 2007 150 154
22. S. Schneeweiss, J.J. Gagne, R.J. Glynn, M. Ruhl, and J.A. Rassen Assessing the comparative effectiveness of newly marketed medications: methodological challenges and implications for drug development Clin Pharmacol Ther 90 6 2011 777 790